- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Radiation and chemotherapy are common partners in anticancer therapy for solid tumors, but too often, the combined side effects associated with each mode of therapy can limit how aggressively oncologists can treat their patients. Now, a team of investigators from Vanderbilt University and Washington University in St. Louis, has developed a nanoparticle that only targets irradiated tumors, offering the potential for reducing chemotherapy-associated toxicities and increasing the effectiveness of combination therapy.
Reporting its work in the Journal of Controlled Release, the team of investigators led by Zhoaozhong Han of Vanderbilt University describes how it used a technology known as "phase display" to identify a short peptide that binds specifically to irradiated tumor cells and used that peptide as an agent to target doxorubicin-containing nanoparticles to radiation-treated cells. Tests using cells grown in culture demonstrated that lipid-based nanoparticles decorated with this peptide do not bind to healthy cells, whether irradiated or not, nor to tumor cells that are not irradiated.
To test if this targeting peptide exhibits the same selectivity in a living animal, the investigators dosed mice bearing human tumors with one of two lipid nanoparticles loaded with the anticancer drug doxorubicin: one nanoparticle was decorated with the targeting peptide, while the "control" nanoparticle was coated with a random peptide that showed no binding preference for a particular type of cell. The researchers also attached a fluorescent probe to the nanoparticles in order to track their accumulation in the animals. Each animal had tumors growing on both sides of the body, with the tumors on only one side receiving radiation therapy.
When injected into the tumor-bearing mice, the targeted liposomes accumulated rapidly around the irradiated tumors but not around the tumors that were not irradiated. Similarly, the untargeted nanoparticles were largely excreted. More importantly, irradiated tumors treated with the targeted nanoparticle showed a marked increase in cell death and a substantial decrease in the number of blood vessels infusing those tumors. The researchers note that the use of anticancer nanoparticles targeted to irradiated tumors may make it possible to lower the dose of radiation used to treat tumors without negatively impacting therapeutic outcomes.
About The National Cancer Institute (NCI)
The NCI Alliance for Nanotechnology in Cancer is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat, and prevent cancer. Through its programs and initiatives, the Alliance is committed to building a community of researchers dedicated to using nanotechnology to advance the fight against cancer.
As part of the Center for Strategic Scientific Initiatives, the Alliance for Nanotechnology in Cancer works in concert with other NCI advanced technology initiatives to provide the scientific foundation and team science that is required to transform cancer research and care.
For more information, please click here
National Cancer Institute
Center for Strategic Scientific Initiatives
NCI Office of Cancer Nanotechnology Research (OCNR)
Building 31, Room 10A52
31 Center Drive, MSC 2580
Bethesda, MD 20892-2580
Telephone: (301) 451-8983
Copyright © The National Cancer Institute (NCI)If you have a comment, please Contact us.
|Related News Press|
News and information
Producing spin-entangled electrons July 2nd, 2015